Trastuzumab with trimodality treatment for oesophageal adenocarcinoma with HER2 overexpression (NRG Oncology/RTOG 1010): a multicentre, randomised, phase 3 trial

Authors: Seaward, Samantha A | The Lancet. Oncology | January 14, 2022 | PubMed abstract

Explore all publications

Back To Top